Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOURCE trial of tezepelumab for oral corticosteroid reduction in severe asthma
2017-003079-69Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in severe asthma and asthma comparing Tezepelumab with Placebo (2 arms). Primary endpoint: Categorized percent reduction from baseline in the daily oral corticosteroid dose at Week 48 while not losing asthma control. Started Dec 2017; status: completed.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2017-003079-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003079-69.